Literature DB >> 33790990

Pro-organic radical contrast agents ("pro-ORCAs") for real-time MRI of pro-drug activation in biological systems.

Hung V-T Nguyen1,2,3,4,5, Alexandre Detappe2,3,4,6,5, Peter Harvey7, Nolan Gallagher1, Clelia Mathieu3,4, Michael P Agius3,4, Oksana Zavidij3,4, Wencong Wang1, Yivan Jiang1, Andrzej Rajca8, Alan Jasanoff7,9,10, Irene M Ghobrial3,4, P Peter Ghoroghchian2,3,4, Jeremiah A Johnson1,2.   

Abstract

Nitroxide-based organic-radical contrast agents (ORCAs) are promising as safe, next-generation magnetic resonance imaging (MRI) tools. Nevertheless, stimuli-responsive ORCAs that enable MRI monitoring of prodrug activation have not been reported; such systems could open new avenues for prodrug validation and image-guided drug delivery. Here, we introduce a novel "pro-ORCA" concept that addresses this challenge. By covalent conjugation of nitroxides and drug molecules (doxorubicin, DOX) to the same brush-arm star polymer (BASP) through chemically identical cleavable linkers, we demonstrate that pro-ORCA and prodrug activation, i.e., ORCA and DOX release, leads to significant changes in MRI contrast that correlate with cytotoxicity. This approach is shown to be general for a range of commonly used linker cleavage mechanisms (e.g., photolysis and hydrolysis) and release rates. Pro-ORCAs could find applications as research tools or clinically viable "reporter theranostics" for in vitro and in vivo MRI-correlated prodrug activation.

Entities:  

Year:  2020        PMID: 33790990      PMCID: PMC8009311          DOI: 10.1039/d0py00558d

Source DB:  PubMed          Journal:  Polym Chem        ISSN: 1759-9954            Impact factor:   5.582


  72 in total

1.  Dual Functionalized Bacteriophage Qβ as a Photocaged Drug Carrier.

Authors:  Zhuo Chen; Na Li; Luxi Chen; Jiyong Lee; Jeremiah J Gassensmith
Journal:  Small       Date:  2016-06-28       Impact factor: 13.281

2.  Polymeric Nanoparticles with a Glutathione-Sensitive Heterodimeric Multifunctional Prodrug for In Vivo Drug Monitoring and Synergistic Cancer Therapy.

Authors:  Fuwu Zhang; Qianqian Ni; Orit Jacobson; Siyuan Cheng; Arthur Liao; Zhantong Wang; Zhimei He; Guocan Yu; Jibin Song; Ying Ma; Gang Niu; Longjiang Zhang; Guizhi Zhu; Xiaoyuan Chen
Journal:  Angew Chem Int Ed Engl       Date:  2018-05-14       Impact factor: 15.336

Review 3.  Clinically Approved Nanoparticle Imaging Agents.

Authors:  Avnesh S Thakor; Jesse V Jokerst; Pejman Ghanouni; Jos L Campbell; Erik Mittra; Sanjiv S Gambhir
Journal:  J Nucl Med       Date:  2016-10-13       Impact factor: 10.057

4.  Contrast agents for MRI: 30+ years and where are we going?

Authors:  Valérie C Pierre; Matthew J Allen; Peter Caravan
Journal:  J Biol Inorg Chem       Date:  2014-01-11       Impact factor: 3.358

5.  Polyoxazoline-Based Bottlebrush and Brush-Arm Star Polymers via ROMP: Syntheses and Applications as Organic Radical Contrast Agents.

Authors:  Gabriela Gil Alvaradejo; Hung V-T Nguyen; Peter Harvey; Nolan M Gallagher; Dao Le; M Francesca Ottaviani; Alan Jasanoff; Guillaume Delaittre; Jeremiah A Johnson
Journal:  ACS Macro Lett       Date:  2019-04-04       Impact factor: 6.903

6.  Drug-loaded, bivalent-bottle-brush polymers by graft-through ROMP.

Authors:  Jeremiah A Johnson; Ying Y Lu; Alan O Burts; Yan Xia; Alec C Durrell; David A Tirrell; Robert H Grubbs
Journal:  Macromolecules       Date:  2010-12-28       Impact factor: 5.985

7.  Drug delivery systems employing 1,4- or 1,6-elimination: poly(ethylene glycol) prodrugs of amine-containing compounds.

Authors:  R B Greenwald; A Pendri; C D Conover; H Zhao; Y H Choe; A Martinez; K Shum; S Guan
Journal:  J Med Chem       Date:  1999-09-09       Impact factor: 7.446

8.  Multifunctional polymeric micelles as cancer-targeted, MRI-ultrasensitive drug delivery systems.

Authors:  Norased Nasongkla; Erik Bey; Jimin Ren; Hua Ai; Chalermchai Khemtong; Jagadeesh Setti Guthi; Shook-Fong Chin; A Dean Sherry; David A Boothman; Jinming Gao
Journal:  Nano Lett       Date:  2006-11       Impact factor: 11.189

9.  Superparamagnetic iron oxide based MRI contrast agents: Current status of clinical application.

Authors:  Yi-Xiang J Wang
Journal:  Quant Imaging Med Surg       Date:  2011-12

10.  A convergent synthetic platform for single-nanoparticle combination cancer therapy: ratiometric loading and controlled release of cisplatin, doxorubicin, and camptothecin.

Authors:  Longyan Liao; Jenny Liu; Erik C Dreaden; Stephen W Morton; Kevin E Shopsowitz; Paula T Hammond; Jeremiah A Johnson
Journal:  J Am Chem Soc       Date:  2014-04-11       Impact factor: 15.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.